CLINICAL TRIALS PROFILE FOR BENZYL BENZOATE
✉ Email this page to a colleague
All Clinical Trials for benzyl benzoate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00119483 ↗ | Older Men and Testosterone | Completed | University Hospital of North Norway | N/A | 2005-09-01 | Male hypogonadism is a clinical situation characterized by a low serum testosterone level in combination with a diversity of symptoms and signs such as reduced libido and vitality, decreased muscle mass, increased fat mass and depression. Similar symptoms in combination with subnormal testosterone levels are seen in some elderly men. Low testosterone levels are associated with known cardiovascular risk factors, and men with diabetes and stroke have lower testosterone levels than healthy men. Even though several publications have suggested that testosterone treatment in hypogonadal men may have beneficial effects, it is still uncertain if testosterone substitution in the aging man is indicated. Despite this uncertainty the sale of testosterone has increased enormously the last few years. We hypothesize that older men with subnormal testosterone levels have a varying degree of dysfunction/symptoms both physically and mentally, and that these dysfunction/symptoms can be improved with testosterone treatment. |
| NCT02927210 ↗ | Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015) | Recruiting | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 | 2016-12-01 | This is a Phase I multicenter, double-blind, single dose, dose-ranging study, in healthy men to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of Dimethandrolone Undecanoate (DMAU) administered as an intramuscular or subcutaneous injection. |
| NCT02927210 ↗ | Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015) | Recruiting | Los Angeles Biomedical Research Institute | Phase 1 | 2016-12-01 | This is a Phase I multicenter, double-blind, single dose, dose-ranging study, in healthy men to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of Dimethandrolone Undecanoate (DMAU) administered as an intramuscular or subcutaneous injection. |
| NCT02927210 ↗ | Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015) | Recruiting | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Phase 1 | 2016-12-01 | This is a Phase I multicenter, double-blind, single dose, dose-ranging study, in healthy men to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of Dimethandrolone Undecanoate (DMAU) administered as an intramuscular or subcutaneous injection. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for benzyl benzoate
Condition Name
Clinical Trial Locations for benzyl benzoate
Trials by Country
Clinical Trial Progress for benzyl benzoate
Clinical Trial Phase
Clinical Trial Sponsors for benzyl benzoate
Sponsor Name
| Sponsor Name for benzyl benzoate | |
| Sponsor | Trials |
| Los Angeles Biomedical Research Institute | 1 |
| Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 1 |
| University of Washington | 1 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
